VibioSphen is a SME healthcare biotechnology in infectious diseases founded in 2014. It focuses its activities on the challenge of antibiotic resistance and nosocomial infections. Its Research & Innovation (R&I) develops new immune modulator treatments complementary to antibiotics.To meet this goal VibioSphen has developed and proposes a scientific platform dedicated to study and validate new compounds and therapies. VibioSphen is an innovative company which provides services for pre-clinical assessments of new therapies on a broad catalogue of mouse experimental and in vitro predictive models from standard to custom-made models. His platform leads research permanently to improve the translational relevance to clinical cases and to provide new models
Vivexia is a french CRO company and offers a wide range of preclinical in-vivo models that enable the evaluation of anti-infective candidates (antibiotics, non antibiotics, phages, immunotherapies...) to prevent or treat life threatening infections arising from Gram-positive and Gram-negative bacteria.